Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
Van Emburgh, B.O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., Valtorta, E., Vidal, J., Bellosillo, B., Germano, G., Pietrantonio, F., Ponzetti, A., Albanell, J., Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Montagut, C. and Bardelli, A.
Notes: The authors purified ctDNA from 1ml plasma using the Maxwell® RSC ccfDNA Plasma Kit with the Maxwell® RSC Instrument. Cell line mismatch repair deficiency was confirmed by the MSI Analysis System, Version 1.2. Cell line authentication was performed using the Cell ID™ and GenePrint® 10 Systems. DNA from cultured and treated cells were purified with the Wizard® SV and SV 96 Genomic DNA Purification Systems. Cetuximab-treated cells were measured for viability with the CellTiter-Glo® Luminescent Cell Viability Assay. (4777)
Expand Full Notes »